ライフサイエンスコーパス: DEN

1 DEN administration caused greater increases in serum int

2 DEN administration increased the levels of malondialdehy

3 DEN exposure promoted production of IL-6 in Kupffer cell

4 DEN treatment also reduced survival of LKO mice compared

5 DEN treatment induced p53-independent PUMA expression, P

6 DEN-1 was subsequently detected by RT-PCR from cell cult

7 DEN-2 genome RNA failed to accumulate in FB 9.1 cells af

8 DEN-induced HCCs with constitutive Notch2 signaling (DEN

9 DEN/PB treatment was associated with specific degradatio

10 e elucidate the role of human deneddylase-1 (DEN-1, also called SENP8) in inflammatory responses in v

11 uble fragment E (sE) of dengue virus type 1 (DEN-1).

12 from the patient, confirmed dengue virus 1 (DEN-1) infection.

13 virus serotypes, i.e., DEN-1 (strain 16007), DEN-2 (16681), DEN-3 (16562), and DEN-4 (1036) viruses b

14 , i.e., DEN-1 (strain 16007), DEN-2 (16681), DEN-3 (16562), and DEN-4 (1036) viruses by over 4 log10,

15 inhibit replication of DEN virus serotype 2 (DEN-2 virus) in mammalian cell culture.

16 four genotypes) of dengue virus serotype 2 (DEN-2) can induce the development of human-like disease,

17 f IFN-alpha against dengue virus serotype 2 (DEN-2).

18 ived from the genome of dengue virus type 2 (DEN-2) capable of forming dsRNA.

19 broad neutralizing activity against 19 of 20 DEN subtypes.

20 The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previo

21 eans of weekly oral gavage with 5 mL of 1.5% DEN solution per kilogram of body weight for 3-11 weeks,

22 at constitutive Notch2 signaling accelerates DEN-induced HCC formation.

23 by alternately passaging a non-mouse-adapted DEN strain between mosquito cells and mice, thereby mimi

24 Additionally, DEN(N2ICD) mice develop large hepatic cysts, dysplasia o

25 not develop liver cancer with age and after DEN injections due to failure to activate gankyrin and e

26 ver nuclear extracts of both genotypes after DEN exposure, the complex formed in MTKO mice was predom

27 e, treatment with an IRAK1/4 inhibitor after DEN administration reduced serum IL-6 levels and liver t

28 , resulting in diminished liver injury after DEN exposure.

29 Apoptosis assays performed monthly after DEN treatment showed no differences between mutant and w

30 Nine months after DEN, SV1 transgenic mice with Klf6 depletion had the gre

31 mmatory cytokines in LKO liver shortly after DEN exposure indicates predisposition of a pro-tumorigen

32 ers of serum neutralizing antibodies against DEN-4.

33 S exhibited hepatoprotective effects against DEN/CCl4-induced injury by reducing DCLK1 expression and

34 ole in the antiviral activity of IFN against DEN-2 replication.

35 MRI and liver histology of alcohol+DEN mice shows hepatobiliary cysts, early hepatic neopla

36 HP potentially can be useful for alleviating DEN infection-associated symptoms by reducing titers of

37 in 16007), DEN-2 (16681), DEN-3 (16562), and DEN-4 (1036) viruses by over 4 log10, in most cases to b

38 The 5' cap and DEN 3' UTR were the main sources of the translational ef

39 so seen in the (D)(V/K) results with DMN and DEN for the minor products resulting from the denitrosat

40 P450 2E1 oxidized DMN and DEN to aldehydes and then to the carboxylic acids.

41 n the pre-steady-state oxidations of DMN and DEN to aldehydes.

42 eled) aldehydes in the oxidations of DMN and DEN to carboxylic acids.

43 parameters measured for oxidation of DMN and DEN to the aldehydes and for oxidation of the aldehydes

44 DMN and DEN were also oxidized to HCO(2)H and CH(3)CO(2)H, respe

45 western blot analysis in both human HCC and DEN-induced murine tumors.

46 Both IR and DEN induced mdr1b in wild-type animals, but not in the p

47 CCC formation in patients and DEN(N2ICD) mice is accompanied by re-expression of hepat

48 rom mosquito-borne flaviviruses (WN-rED3 and DEN-rED3) were similar to each other yet distinct from r

49 and increases rates of both spontaneous and DEN carcinogen-induced HCC.

50 HCA and HCC in DEN/carbon tetrachloride and DEN/TCPOBOP induced liver tumors.

51 A effectively inhibited HepG2-xenografts and DEN-induced-HCC in C57BL/6 mice.

52 Analyses of WA-treated HepG2-xenografts and DEN-induced-HCC tumors showed elevated levels of ERK, RS

53 The signaling events and anti-DEN-2 activities of IFN-alpha and IFN-gamma were reduced

54 lly hybridized to labeled sense or antisense DEN-2 RNA derived from the target region of the genome.

55 tential use in a recombinant live attenuated DEN vaccine.

56 ocyte-specific deletion of IKKbeta augmented DEN-induced hepatocyte death and cytokine-driven compens

57 Importantly, LNPs were also able to boost DEN-80E specific CD4+ and CD8+ T cell responses.

58 matically reduced the LNP's ability to boost DEN-80E specific immune responses, highlighting the cruc

59 HCC or core-enhanced HCC incidence caused by DEN/Pb.

60 to TNF-alpha, whose expression is induced by DEN, and JNK activity is required for normal hepatocyte

61 he oxidative stress and apoptosis induced by DEN.

62 n be initiated by exposure to the carcinogen DEN, which has been shown to rely upon activation of NF-

63 se FGF21 is induced in response to chemical (DEN treatment) and genetic-induced hepatocarcinogenesis

64 backbone reversion, the safety of ChimeriVax-DEN vaccines would not be compromised.

65 sions produced by the tetravalent ChimeriVax-DEN vaccine were significantly less severe than those ob

66 yellow fever virus-dengue virus (ChimeriVax-DEN) vaccine candidates against dengue virus types 1 to

67 onstruct chimeric YF/DEN viruses (ChimeriVax-DEN), the premembrane (prM) and envelope (E) genes of ye

68 The immune factors that control DEN infection or contribute to severe disease are neithe

69 in impairs the liver's ability to counteract DEN-induced oxidative stress and enhances tumorigenesis

70 emonstrating that RIPK1 deficiency decreases DEN-induced liver tumor formation in a TNFR1-dependent m

71 Dengue (DEN) is a mosquito-borne disease caused by four DENV ser

72 lammatory cytokines induced during a dengue (DEN) virus infection plays a role in either protection o

73 a worst-case recombinant, ChimeriVax-dengue (DEN) 4 virus was chimerized with the WT Asibi yellow fev

74 The mosquito-borne disease dengue (DEN) is caused by four serologically and genetically rel

75 Five dengue (DEN) virus-specific R5F2R4 peptide-conjugated phosphorod

76 s of previously described monovalent dengue (DEN) virus vaccine candidates were compared to a tetrava

77 guanosine cap-binding pocket of the dengue (DEN) and yellow fever (YF) virus MTase enzymes.

78 ed with those of each wild-type (WT) dengue (DEN) virus representing serotypes 1 to 4.

79 Diethylnitrosamine (DEN) injection induce DSBs along with elevation in the n

80 Diethylnitrosamine (DEN)/carbon tetrachloride (CCl4) extensively induced exp

81 ependent apoptosis, in a diethylnitrosamine (DEN)-induced liver carcinogenesis model.

82 ing HCC in response to a Diethylnitrosamine (DEN)/Phenobarbital (PB) liver tumor-induction protocol.

83 s of mice treated with a diethylnitrosamine (DEN)/phenobarbital tumor induction protocol.

84 eed oil extracts against diethylnitrosamine (DEN) and phenobarbital (PB) induced hepatic injury in ra

85 tocytes protects against diethylnitrosamine (DEN)-induced HCC.

86 f c-Fos protects against diethylnitrosamine (DEN)-induced HCCs, whereas liver-specific c-Fos expressi

87 ular carcinoma (HCC) and diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis.

88 (NO) in spontaneous and diethylnitrosamine (DEN)-initiated and/or phenobarbital (Pb)-promoted HCC de

89 arcinogenesis induced by diethylnitrosamine (DEN) produced large carcinomas in all AhR-/- mice but mo

90 cinogenesis triggered by diethylnitrosamine (DEN).

91 carcinogenesis caused by diethylnitrosamine (DEN).

92 to the liver carcinogen diethylnitrosamine (DEN) and fed diets with well-defined sugar and fat conte

93 tiated by the carcinogen diethylnitrosamine (DEN).

94 known hepatic carcinogen diethylnitrosamine (DEN).

95 epatocellular carcinogen diethylnitrosamine (DEN).

96 n a chemical carcinogen, diethylnitrosamine (DEN).

97 y the genotoxic chemical diethylnitrosamine (DEN), a hepatic carcinogen that is not an AHR ligand.

98 njection of 10 micro g/g diethylnitrosamine (DEN) and continued administration of phenobarbital (PB)

99 by the hepatocarcinogen diethylnitrosamine (DEN).

100 to the hepatocarcinogen diethylnitrosamine (DEN).

101 ith the hepatocarcinogen diethylnitrosamine (DEN).

102 ation of liver cancer in diethylnitrosamine (DEN)-treated CUGBP1-S302A mice showed these mice develop

103 hout the tumor initiator diethylnitrosamine (DEN) at 5 weeks of age and then orally inoculated with H

104 itrosamine (DMN) and N,N-diethylnitrosamine (DEN), to alkyl diazohydroxides (which are DNA-alkylating

105 nitrosodiethylamine [N,N-diethylnitrosamine (DEN)], the intrinsic KIE was slightly lower and was not

106 ed with a combination of diethylnitrosamine (DEN) and CCl4, along with either LPS or E. coli infectio

107 raperitoneal delivery of diethylnitrosamine (DEN), a known carcinogen, induced HCC at 6 months in TG

108 , low-dose injections of diethylnitrosamine (DEN), a mouse model induced by carbon tetrachloride (CCl

109 er a single injection of diethylnitrosamine (DEN), SV1 hepatocyte transgenic mice developed more hist

110 rates the development of diethylnitrosamine (DEN)-induced hepatocellular carcinoma.

111 ose (200 mg/kg, i.p.) of diethylnitrosamine (DEN).

112 peritoneal injections of diethylnitrosamine (DEN); 2 weeks later, some mice also received left and me

113 Using the procarcinogen diethylnitrosamine (DEN) to initiate tumorigenesis in mice, we discovered th

114 We show that diethylnitrosamine (DEN)-induced murine HCC is attenuated by antibody-mediat

115 Using the diethylnitrosamine (DEN) HCC carcinogenesis model, we further show that cons

116 In this study, the diethylnitrosamine (DEN)-induced liver tumor model and the chronic carbon te

117 In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated

118 WT) mice were exposed to diethylnitrosamine (DEN) and induction of HCC was monitored at 23 and 33 wee

119 much more susceptible to diethylnitrosamine (DEN)-induced acute liver injury and liver carcinogenesis

120 are hypersusceptible to diethylnitrosamine (DEN)-induced hepatocarcinogenesis.

121 ground were treated with diethylnitrosamine (DEN) and sacrificed at 32 weeks old.

122 Cre; Rosa(YFP) mice with diethylnitrosamine (DEN), followed by multiple injections of carbon tetrachl

123 Diethylnitrosoamine (DEN)-mediated liver cancer in wild-type mice also involv

124 ent DNA damaging agent, diethylnitrosoamine (DEN).

125 y neutralizing against genotypically diverse DEN-4 viruses.

126 iters of all four DEN virus serotypes, i.e., DEN-1 (strain 16007), DEN-2 (16681), DEN-3 (16562), and

127 -derived dendritic cell cultures with either DEN or Sindbis virus, another positive-strand RNA virus,

128 gnant hepatocyte transformation and enhanced DEN-carcinogenesis.

129 RB deletion in the mouse liver enhances DEN-induced tumorigenesis, associated with increased hep

130 DCLD RNA contained the entire DEN 5' and 3' untranslated regions (UTRs), as well as th

131 satory proliferation and prevented excessive DEN-induced carcinogenesis in Ikkbeta(Deltahep) mice.

132 based on the percentage of cells expressing DEN-2 envelope (E) antigen 7 days after challenge.

133 cantly up-regulated in livers of alcohol-fed DEN-injected mice compared to controls.

134 Here we show that alcohol-fed DEN-injected mice have higher ALT and liver-to-body weig

135 er-to-body weight ratio compared to pair-fed DEN-injected mice.

136 ion (LMBDL) and, then 1 week later, were fed DEN, in corn oil, weekly by oral gavage (DLD).

137 mutagenic O6-ethyldeoxyguanosines following DEN challenge in livers of GSNOR-deficient (GSNOR(-/-))

138 otably, short-term iNOS inhibition following DEN treatment had little effect on carcinogenesis in wil

139 osis and compensatory regeneration following DEN treatment, and does not require the HBV X protein.

140 precursors improves cell survival following DEN treatment to a level indistinguishable from ACC-defi

141 At 35 weeks following DEN exposure, LKO mice exhibited a higher incidence of m

142 The (D)k(app) for DEN was approximately 3 and not expressed in non-competi

143 0 microM 3'CS reduced the titers of all four DEN virus serotypes, i.e., DEN-1 (strain 16007), DEN-2 (

144 ) formulation seroconverted against all four DEN virus serotypes.

145 with TV-1 and TV-3 seroconverted to the four DEN components by day 28 with neutralization titers rang

146 o aldehydes (HCHO from DMN and CH(3)CHO from DEN).

147 iferative genes when compared with HCCs from DEN-induced control mice (DEN(ctrl) HCCs).

148 ation of which also protected male mice from DEN-induced hepatocarcinogenesis.

149 after stimulation with Ags from heterologous DEN serotypes.

150 educed circulating concentrations of IL-6 in DEN-treated male mice.

151 tivation was also significantly augmented in DEN-exposed MTKO livers.

152 liver weights were significantly greater in DEN-treated wild-type or heterozygous mice.

153 tes are the cell of origin of HCA and HCC in DEN/carbon tetrachloride and DEN/TCPOBOP induced liver t

154 iated compensatory proliferation observed in DEN-injured ERRalpha-null livers is concomitant with inc

155 chemokine receptor-4 (CXCR4), was reduced in DEN-induced MMP10-deficient mice livers.

156 Despite the oncogenic function of STAT3 in DEN-induced liver tumor, hepatocyte-specific STAT3 knock

157 umors and surrounding normal liver tissue in DEN-treated HNF4alpha knockout mice showed significant i

158 ed to complete abolition of tumorigenesis in DEN-exposed beta-cat KO.

159 gamma and TNF-alpha responses to inactivated DEN Ags were detected in up to 0.54 and 1.17% of total c

160 tumorigenesis that correlated with increased DEN-induced hepatocyte apoptosis.

161 also suppressed diethylnitrosamine-induced (DEN-induced) hepatocarcinogenesis, as an increased numbe

162 1 showed reduced diethylnitrosamine-induced (DEN-induced) liver tumorigenesis that correlated with in

163 ack of RIPK1 kinase activity did not inhibit DEN-induced liver tumor formation, showing that kinase-i

164 eriments showed that 5'SL and 3'CS inhibited DEN-2 virus replication in a dose-dependent and sequence

165 beta receptor-mediated action limits initial DEN replication in extraneural sites and controls subseq

166 begins to provide mechanistic insights into DEN-induced disease in vivo.

167 controls were given a single intraperitoneal DEN injection and followed for 6-12 months for hepatic t

168 an isolate, which can be used to investigate DEN pathogenesis and to evaluate candidate vaccines and

169 s in which translation factors are limiting, DEN can alternate between canonical cap-dependent transl

170 red with HCCs from DEN-induced control mice (DEN(ctrl) HCCs).

171 ived experimental live attenuated monovalent DEN vaccines.

172 Moreover, DEN(N2ICD) HCCs exhibit increased Sox9 messenger RNA (mR

173 tudy, the use of a dopant enriched nitrogen (DEN)-gas combined with sheathless capillary electrophore

174 the chemical carcinogen diethyl nitrosamine (DEN) than wild-type animals.

175 oma after initiation by diethyl-nitrosamine (DEN).

176 We examined N-nitrosodiethylamine (DEN)-induced tumorigenesis in hepatic beta-catenin condi

177 , with more than 95% of the cells showing no DEN-2 antigen accumulation.

178 Notably, DEN-treated Hh-infected KO mice exhibited increased numb

179 el that is more relevant to DHF/DSS, a novel DEN strain, D2S10, was generated by alternately passagin

180 These HP facilitate rapid binding of DEN to human and monkey E in vitro, with approximately 9

181 g the steady state promoted rapid binding of DEN to the E, followed by subsequent clearance from the

182 crucial for both early and late clearance of DEN infection in mice, and (iii) the IFN system plays a

183 y models, so we examined the contribution of DEN-1 to HIF stabilization.

184 Initial growth curves of DEN-2 virus 16681 were obtained in Vero cells incubated

185 expression contributes to the development of DEN-mediated carcinogenesis by promoting the proliferati

186 tly capturing a subsequent challenge dose of DEN and binding it to E.

187 The effect of DEN-gas on the repeatability and intermediate precision

188 dinal feature of DHF/DSS, the severe form of DEN infection, is increased vascular permeability.

189 ction relationships in the E glycoprotein of DEN virus and provide the first direct evidence that dom

190 may play a role in the immunopathogenesis of DEN hemorrhagic fever.

191 ished by continuous steady state infusion of DEN, injection of HP during the steady state promoted ra

192 In mice given a single i.p. injection of DEN, AHR antagonized liver tumor formation and growth by

193 Knockdown of DEN-1 in human intestinal epithelial cells resulted in i

194 apoptotic defects developed in the livers of DEN-treated TRAIL-R-/- mice.

195 re identified at 32 weeks in the majority of DEN-treated mice from all three groups.

196 tion after PH, as well as the progression of DEN-induced tumors, providing evidence for a functional

197 ed hepatocyte proliferation and promotion of DEN-induced hepatic tumors secondary to aberrant c-Myc a

198 Although hepatocytes in nontumor regions of DEN-exposed livers were quiescent regardless of RB statu

199 for their ability to inhibit replication of DEN virus serotype 2 (DEN-2 virus) in mammalian cell cul

200 and characterized the cytokine responses of DEN virus-specific memory CD4+ T cells in PBMC of six vo

201 gnificantly increased the number and size of DEN-induced hepatic tumors.

202 ed in the livers of control and, more so, of DEN-exposed Ahr-/- mice.

203 ted responses seem to act at later stages of DEN disease by restricting viral replication in the peri

204 -PMO showed relatively little suppression of DEN-2 virus titer (0.1 and 0.9 log10, respectively).

205 tration of an antioxidant around the time of DEN exposure blocked prolonged JNK activation and compen

206 The use of DEN-gas opens new avenues for highly sensitive sheathles

207 he enhanced repeatability fosters the use of DEN-gas sheathless CE-ESI-MS in protein glycosylation an

208 Daily treatment of 6-month-old DEN-exposed beta-cat KO with PDGFRalpha inhibitor dramat

209 ogenesis and hepatocarcinogenesis in mice on DEN challenge by up-regulating several genes involved in

210 ed the influence of cellular growth state on DEN type 2 (DEN2) replication in mosquito and human cell

211 ngiocarcinoma, compared with mice given only DEN.

212 ollowing the first oxidation (i.e. of DMN or DEN to an aldehyde).

213 effect was observed for RNAs with globin or DEN 5' sequences, indicating no codependency between vir

214 In contrast, mice infected with the parental DEN strain developed paralysis at late times after infec

215 ce infected with D2S10, but not the parental DEN strain, significant levels of serum tumor necrosis f

216 mice with diethylnitrosamine/phenobarbital (DEN/PB), which induces formation of liver cancer, actual

217 l and seed oil extracts pre, during and post DEN administration improved liver functions, decreased t

218 At 25 weeks post-DEN injection, all LKO mice developed CK-19-positive hep

219 of the 5'SL and 3'CS compounds as potential DEN virus therapeutics is warranted.

220 way controls later viral burden and prevents DEN disease in mice.

221 trate that IFNR-dependent control of primary DEN infection involves both STAT1-dependent and STAT1-in

222 onoverlapping functions in resolving primary DEN infection.

223 -dependent immunity in resistance to primary DEN infection in mice.

224 1-independent responses in mice with primary DEN infection included the early activation of B and NK

225 inase-independent functions of RIPK1 promote DEN-induced hepatocarcinogenesis.

226 cts downstream of TNFR1 signaling to promote DEN-induced liver tumorigenesis.

227 These PPF/Al2O3/Pt DEN electrodes were completely stable under a variety of

228 The resulting Pt DEN films were electrocatalytically active for the oxyge

229 t to demonstrate the safety of a recombinant DEN virus tetravalent vaccine in a formal neurovirulence

230 r structures clarify the previously reported DEN MTase structure, suggest novel protein-cap interacti

231 y of the four related dengue virus serotypes DEN-1, -2, -3 and -4, which are transmitted to people by

232 rotein from all four Dengue virus serotypes (DEN-80E) formulated with ionizable cationic lipid nanopa

233 nificant advance in animal models for severe DEN disease, and it begins to provide mechanistic insigh

234 ay be one of several key mediators of severe DEN-induced disease in mice.

235 ced HCCs with constitutive Notch2 signaling (DEN(N2ICD) HCCs) exhibit a marked increase in size, prol

236 t to liver tumorigenesis induced by a single DEN injection, whose tumorigenesis was associated with m

237 and TV-3, possess properties of a successful DEN vaccine and can be considered for evaluation in clin

238 expression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tu

239 of a small-animal model that mimics systemic DEN disease without neurovirulence has been an obstacle,

240 3 model provides a relevant platform to test DEN vaccines and antivirals.

241 and DEN4 viruses suggests that a tetravalent DEN vaccine could be generated by introduction of the De

242 ating that they are less differentiated than DEN(ctrl) HCCs.

243 We conclude that DEN-1 is a regulator of cullin neddylation and fine-tune

244 l examination of liver tissue confirmed that DEN-treated ATX mice developed approximately twice as ma

245 This report demonstrates that DEN replication and translation are not affected under c

246 Our results suggest that DEN-treated mice provide an excellent model for human he

247 ense and antisense polarity, suggesting that DEN-2-specific dsRNA was present in the cells.

248 The DEN 3' UTR increased mRNA stability, although this effec

249 The DEN 3' UTR thus has translational regulatory properties

250 at translational enhancement provided by the DEN 3' UTR is attributable to the cumulative contributio

251 try site but requires the interaction of the DEN 5' and 3' UTRs for activity, suggesting a novel stra

252 Furthermore, the structures of the DEN and YF proteins are essentially identical, indicatin

253 mentary to cCS1 present in the 5' end of the DEN polyprotein open reading frame.

254 ession of 5'- and 3'-terminal regions of the DEN serotype 2 genome by using luciferase reporter mRNAs

255 -shaped concavity observed at the tip of the DEN-2 sE trimer.

256 targeting the 3'-terminal nucleotides of the DEN-2 virus genome and a random-sequence P4-PMO showed r

257 One of the DEN-2-resistant cell lines, FB 9.1, was further characte

258 However, the means by which the DEN genome is translated effectively in the presence of

259 nt increase in foci volume compared with the DEN controls.

260 This DEN noncanonical translation is not mediated by an inter

261 ased tumor multiplicity in livers exposed to DEN.

262 eptibility of mice lacking the AEG-1 gene to DEN-induced hepatocarcinogenesis.

263 EGFR inhibitor erlotinib delivered prior to DEN-induced injury was sufficient to block compensatory

264 silencing as the mechanism of resistance to DEN-2 in transformed mosquito cells.

265 AEG-1-deficient mice displayed resistance to DEN-induced HCC and lung metastasis.

266 designed to express irRNA were resistant to DEN-2 challenge, with more than 95% of the cells showing

267 ocyte necrosis over apoptosis in response to DEN due to a deficiency in energy production.

268 udy the immune mechanisms in the response to DEN infection.

269 played normal tumor formation in response to DEN, demonstrating that RIPK1 deficiency decreases DEN-i

270 ta is critical for early immune responses to DEN infection, (ii) IFN-gamma-mediated immune responses

271 ix metalloproteinases were more sensitive to DEN induction in the absence of TGR5 signaling.

272 examined whether increased susceptibility to DEN-induced hepatocarcinogenesis in Ikkbeta(Deltahep) mi

273 a paradoxical increase in susceptibility to DEN-induced tumorigenesis.

274 ) T cells had no increased susceptibility to DEN; however, RAG mice (deficient in both B and T cells)

275 B and T cells) were partially susceptible to DEN infection.

276 overexpression makes TG mice susceptible to DEN-induced HCC.

277 e lacking JNK1 were much less susceptible to DEN-induced hepatocarcinogenesis.

278 ese defects and reversed unresponsiveness to DEN-induced liver injury and malignant development.

279 ed to a tetravalent formulation of wild-type DEN viruses (T-wt) for replication in SCID mice transpla

280 el of toxin-induced hepatic neoplasia, using DEN and 3,3',5,5'-tetrachloro-1,4-bis(pyridyloxy)benzene

281 Dengue virus (DEN) and other flaviviruses, such as West Nile and yello

282 Dengue virus (DEN) causes dengue fever and dengue hemorrhagic fever/de

283 c RNAs of flaviviruses such as dengue virus (DEN) have a 5' m7GpppN cap like those of cellular mRNAs

284 Dengue virus (DEN) is the most prevalent cause of arthropod-borne vira

285 Dengue virus (DEN), a flavivirus, causes dengue fever and dengue hemor

286 n appropriate animal model for dengue virus (DEN), which causes dengue fever and dengue hemorrhagic f

287 Dengue viruses (DEN), causative agents of dengue fever (DF) and more sev

288 mice and treated the resulting animals with DEN/Phenobarbital, an established protocol for liver car

289 biotic resistance marker and challenged with DEN-2.

290 e hepatobiliary cysts, which correlated with DEN-induced transcriptional activation of Cdc25a mediate

291 d to controls at 6 days after infection with DEN-2 virus.

292 Treatment of mice with DEN resulted in a six- to eightfold increase in the muta

293 similar values were found for CE-ESI-MS with DEN-gas.

294 for liver tumorigenesis in mice treated with DEN, and identifies an important role for ACC enzymes in

295 hepatitis in WT and KO mice with or without DEN that correlated with significant upregulation of Tnf

296 introduction of the Delta30 mutation into wt DEN viruses belonging to each of the four serotypes.

297 oculated with either YF/DEN1-4 vaccine or WT DEN virus.

298 describe construction of three additional YF/DEN chimeras using premembrane (prM) and envelope (E) ge

299 To construct chimeric YF/DEN viruses (ChimeriVax-DEN), the premembrane (prM) and

300 r, four of nine monkeys in the monovalent YF/DEN groups developed low levels of viremia, whereas no v